{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:56:29Z","timestamp":1792173389743,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T00:00:00Z","timestamp":1595030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T00:00:00Z","timestamp":1595030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Irish Clinical Academic Training Programme","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK118528-01A1"],"award-info":[{"award-number":["DK118528-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The prevalence of Gestational Diabetes (GDM) is rising and with it the number of mothers and children at risk of adverse outcomes. As treatment has been shown to reduce adverse events, it is imperative that we identify all at-risk pregnant women. In Ireland, the national standard of care is selective screening with a 2-hour 75\u00a0g oral glucose tolerance test (OGTT). Aiming for universal screening is of utmost importance but this is difficult given the length, the unfeasibility and impracticability of the OGTT. We aim to assess if the novel biomarker glycated CD59 (gCD59) is a suitable contender for the OGTT in identifying women with GDM.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In this prospective cohort study, the study participants will be consecutive pregnant women at Galway University Hospital, Galway, Ireland. Samples for the plasma gCD59 biomarker will be taken together with routine bloods at the first antenatal visit, at weeks 24\u201328\u00a0at the time of routine 75\u00a0g OGTT, in trimester 3- and 12-weeks post-partum for women with GDM while having their routine post-partum 75\u00a0g OGTT. The constructed database will contain baseline information on each study participant, baseline laboratory data, follow-up laboratory data and pregnancy related outcomes. We aim to recruit a total of 2,000 participants over the project period and with a national GDM prevalence of 12\u201313%, we will have 240\u2013260 subjects who meet OGTT criteria for GDM. Following regional prevalence, we expect to have 34\u201337 women who will develop either diabetes or pre-diabetes in the early post-partum period. The sensitivity and specificity of plasma gCD59 to predict the results of the OGTT will be assessed using nonparametric estimates of the receiver operating characteristic (ROC) curves and respective area under the ROC curve (AUROC).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>A body of clinical and experimental evidence supports a link between the complement system, complement regulatory proteins, and the pathogenesis of diabetes complications.<\/jats:p>\n<jats:p>Building on this research, our study plans to look at the plasma gCD59 capacity to classify pregnant women with normal or abnormal glucose tolerance but also to assess if plasma gCD59 can be used as an early predictor for GDM, for adverse pregnancy outcomes and\/or post-partum glucose intolerance.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12884-020-03090-9","type":"journal-article","created":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T10:02:33Z","timestamp":1595066553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Plasma glycated CD59 (gCD59), a novel biomarker for the diagnosis, management and follow up of women with Gestational Diabetes (GDM) \u2013 protocol for prospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"D.","family":"Bogdanet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PM.","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,18]]},"reference":[{"issue":"19","key":"3090_CR1","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa0707943","volume":"358","author":"BE Metzger","year":"2008","unstructured":"Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991\u20132002.","journal-title":"N Engl J Med"},{"issue":"3","key":"3090_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc18-1646","volume":"42","author":"WL Lowe","year":"2019","unstructured":"Lowe WL, Scholtens DM, Kuang A, Linder B, Lawrence JM, Lebenthal Y, et al. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Gestational Diabetes and Childhood Glucose Metabolism. Diabetes Care. 2019;42(3):372. .","journal-title":"Diabetes Care"},{"issue":"10","key":"3090_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jama.2018.11628","volume":"320","author":"WL Lowe","year":"2018","unstructured":"Lowe WL, Scholtens DM, Lowe LP, Kuang A, Nodzenski M, Talbot O, et al. Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. JAMA. 2018;320(10):1005\u201316.","journal-title":"JAMA"},{"issue":"4","key":"3090_CR4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1097\/GRF.0b013e31815a61d6","volume":"50","author":"BE Metzger","year":"2007","unstructured":"Metzger BE. Long-term outcomes in mothers diagnosed with gestational diabetes mellitus and their offspring. Clin Obstet Gynecol. 2007;50(4):972\u20139.","journal-title":"Clin Obstet Gynecol"},{"issue":"2","key":"3090_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrendo.2009.265","volume":"6","author":"CA Zera","year":"2010","unstructured":"Zera CA, Seely EW. Diabetes. Treatment of gestational diabetes reduces obstetric morbidity. Nat Rev Endocrinol. 2010;6(2):69\u201370.","journal-title":"Nat Rev Endocrinol"},{"issue":"14","key":"3090_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1056\/NEJMoa0902430","volume":"361","author":"MB Landon","year":"2009","unstructured":"Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339\u201348.","journal-title":"N Engl J Med"},{"issue":"24","key":"3090_CR7","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa042973","volume":"352","author":"CA Crowther","year":"2005","unstructured":"Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477\u201386.","journal-title":"N Engl J Med"},{"issue":"5","key":"3090_CR8","doi-asserted-by":"publisher","first-page":"e023014","DOI":"10.1136\/bmjopen-2018-023014","volume":"9","author":"L Li-Zhen","year":"2019","unstructured":"Li-Zhen L, Yun X, Xiao-Dong Z, Shu-Bin H, Zi-Lian W, Adrian Sandra D, et al. Evaluation of guidelines on the screening and diagnosis of gestational diabetes mellitus: systematic review. BMJ Open. 2019;9(5):e023014.","journal-title":"BMJ Open"},{"issue":"7","key":"3090_CR9","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2337\/dc09-0188","volume":"32","author":"RG Moses","year":"2009","unstructured":"Moses RG, Cheung NW. Point: Universal screening for gestational diabetes mellitus. Diabetes Care. 2009;32(7):1349\u201351.","journal-title":"Diabetes Care"},{"issue":"4","key":"3090_CR10","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/0002-9378(93)90019-F","volume":"169","author":"PM Catalano","year":"1993","unstructured":"Catalano PM, Avallone DA, Drago NM, Amini SB. Reproducibility of the oral glucose tolerance test in pregnant women. Am J Obstet Gynecol. 1993;169(4):874\u201381.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"3090_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.diabres.2003.08.005","volume":"63","author":"MM Agarwal","year":"2004","unstructured":"Agarwal MM, Punnose J, Dhatt GS. Gestational diabetes: problems associated with the oral glucose tolerance test. Diabetes Res Clin Pract. 2004;63(1):73\u20134.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"3090_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2337\/dc11-1641","volume":"35","author":"DA Sacks","year":"2012","unstructured":"Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, Metzger BE, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care. 2012;35(3):526\u20138.","journal-title":"Diabetes Care"},{"issue":"2","key":"3090_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2567.2004.02086.x","volume":"114","author":"CS Davies","year":"2005","unstructured":"Davies CS, Harris CL, Morgan BP. Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects. Immunology. 2005;114(2):280\u20136.","journal-title":"Immunology"},{"issue":"5","key":"3090_CR14","first-page":"532","volume":"65","author":"S Meri","year":"1991","unstructured":"Meri S, Waldmann H, Lachmann PJ. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest. 1991;65(5):532\u20137.","journal-title":"Lab Invest"},{"issue":"4","key":"3090_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1084\/jem.185.4.745","volume":"185","author":"J Yu","year":"1997","unstructured":"Yu J, Abagyan R, Dong S, Gilbert A, Nussenzweig V, Tomlinson S. Mapping the active site of CD59. J Exp Med. 1997;185(4):745\u201353.","journal-title":"J Exp Med"},{"issue":"7","key":"3090_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.placenta.2010.03.010","volume":"31","author":"AM Lynch","year":"2010","unstructured":"Lynch AM, Salmon JE. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta. 2010;31(7):561\u20137.","journal-title":"Placenta"},{"issue":"1","key":"3090_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/aji.12162","volume":"71","author":"MC Hoffman","year":"2014","unstructured":"Hoffman MC, Rumer KK, Kramer A, Lynch AM, Winn VD. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol. 2014;71(1):55\u201360.","journal-title":"Am J Reprod Immunol"},{"issue":"5","key":"3090_CR18","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1161\/HYPERTENSIONAHA.112.194324","volume":"60","author":"A Buurma","year":"2012","unstructured":"Buurma A, Cohen D, Veraar K, Schonkeren D, Claas FH, Bruijn JA, et al. Preeclampsia is characterized by placental complement dysregulation. Hypertension. 2012;60(5):1332\u20137.","journal-title":"Hypertension"},{"issue":"1","key":"3090_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00281-017-0645-x","volume":"40","author":"G Girardi","year":"2018","unstructured":"Girardi G. Complement activation, a threat to pregnancy. Semin Immunopathol. 2018;40(1):103\u201311.","journal-title":"Semin Immunopathol"},{"issue":"9","key":"3090_CR20","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1084\/jem.20061022","volume":"203","author":"G Girardi","year":"2006","unstructured":"Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006;203(9):2165\u201375.","journal-title":"J Exp Med"},{"issue":"Suppl 2","key":"3090_CR21","doi-asserted-by":"publisher","first-page":"ii46","DOI":"10.1136\/ard.61.suppl_2.ii46","volume":"61","author":"JE Salmon","year":"2002","unstructured":"Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002;61(Suppl 2):ii46\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"1\u20132","key":"3090_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molimm.2005.06.017","volume":"43","author":"G Girardi","year":"2006","unstructured":"Girardi G, Bulla R, Salmon JE, Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol. 2006;43(1\u20132):68\u201377.","journal-title":"Mol Immunol"},{"issue":"7","key":"3090_CR23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2337\/dc16-2598","volume":"40","author":"P Ghosh","year":"2017","unstructured":"Ghosh P, Luque-Fernandez MA, Vaidya A, Ma D, Sahoo R, Chorev M, et al. Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-Induced Glucose Intolerance. Diabetes Care. 2017;40(7):981\u20134.","journal-title":"Diabetes Care"},{"issue":"5 Suppl","key":"3090_CR24","first-page":"13","volume":"105","author":"EP O\u2019Sullivan","year":"2012","unstructured":"O\u2019Sullivan EP, Avalos G, O\u2019Reilly M, Dennedy MC, Gaffney G, Dunne FP, et al. Atlantic DIP: the prevalence and consequences of gestational diabetes in Ireland. Ir Med J. 2012;105(5 Suppl):13\u20135.","journal-title":"Ir Med J"},{"issue":"1","key":"3090_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00592-014-0621-z","volume":"52","author":"E Noctor","year":"2015","unstructured":"Noctor E, Crowe C, Carmody LA, Kirwan B, O\u2019Dea A, Glynn LG, et al. ATLANTIC-DIP: prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by International Association of Diabetes in Pregnancy Study Groups criteria. Acta Diabetol. 2015;52(1):153\u201360.","journal-title":"Acta Diabetol"},{"issue":"24","key":"3090_CR26","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1002\/sim.2431","volume":"24","author":"MS Pepe","year":"2005","unstructured":"Pepe MS. Evaluating technologies for classification and prediction in medicine. Stat Med. 2005;24(24):3687\u201396.","journal-title":"Stat Med"},{"issue":"6","key":"3090_CR27","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","volume":"54","author":"M Brownlee","year":"2005","unstructured":"Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615\u201325.","journal-title":"Diabetes"},{"issue":"10","key":"3090_CR28","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1073\/pnas.97.10.5450","volume":"97","author":"J Acosta","year":"2000","unstructured":"Acosta J, Hettinga J, Fl\u00fcckiger R, Krumrei N, Goldfine A, Angarita L, et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A. 2000;97(10):5450\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3090_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nrendo.2009.266","volume":"6","author":"A Flyvbjerg","year":"2010","unstructured":"Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol. 2010;6(2):94\u2013101.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"3090_CR30","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2337\/dc11-1642","volume":"35","author":"LG Mellbin","year":"2012","unstructured":"Mellbin LG, Bjerre M, Thiel S, Hansen TK. Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care. 2012;35(4):911\u20137.","journal-title":"Diabetes Care"},{"issue":"10","key":"3090_CR31","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2337\/diabetes.53.10.2653","volume":"53","author":"X Qin","year":"2004","unstructured":"Qin X, Goldfine A, Krumrei N, Grubissich L, Acosta J, Chorev M, et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes. 2004;53(10):2653\u201361.","journal-title":"Diabetes"},{"issue":"Pt 3","key":"3090_CR32","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1042\/bj3160923","volume":"316","author":"S Meri","year":"1996","unstructured":"Meri S, Lehto T, Sutton CW, Tyynel\u00e4 J, Baumann M. Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Biochem J. 1996;316(Pt 3):923\u201335.","journal-title":"Biochem J"},{"issue":"5","key":"3090_CR33","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/ki.1995.197","volume":"47","author":"T Lehto","year":"1995","unstructured":"Lehto T, Honkanen E, Teppo AM, Meri S. Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int. 1995;47(5):1403\u201311.","journal-title":"Kidney Int"},{"issue":"4","key":"3090_CR34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1046\/j.1365-3083.2000.00783.x","volume":"52","author":"A V\u00e4kev\u00e4","year":"2000","unstructured":"V\u00e4kev\u00e4 A, Lehto T, Takala A, Meri S. Detection of a soluble form of the complement membrane attack complex inhibitor CD59 in plasma after acute myocardial infarction. Scand J Immunol. 2000;52(4):411\u20134.","journal-title":"Scand J Immunol"},{"issue":"6","key":"3090_CR35","doi-asserted-by":"publisher","first-page":"E999","DOI":"10.1210\/jc.2013-4232","volume":"99","author":"P Ghosh","year":"2014","unstructured":"Ghosh P, Vaidya A, Sahoo R, Goldfine A, Herring N, Bry L, et al. Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans. J Clin Endocrinol Metab. 2014;99(6):E999\u20131006.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"3090_CR36","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/ajh.23478","volume":"88","author":"P Ghosh","year":"2013","unstructured":"Ghosh P, Sahoo R, Vaidya A, Cantel S, Kavishwar A, Goldfine A, et al. A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes. Am J Hematol. 2013;88(8):670\u20136.","journal-title":"Am J Hematol"},{"key":"3090_CR37","doi-asserted-by":"crossref","unstructured":"Halperin J, Dongdong M, Luque-Fernandez MA, Bogdanet D, Desoye G, Dunne F. Plasma Glycated CD59 (pGCD59) Predicts Early Gestational Diabetes (GDM) and Abnormal Neonatal Outcomes: DALI Study Secondary Analysis. American Diabetes Association; June 2019; San Francisco: Diabetes; 2019.","DOI":"10.2337\/db19-186-OR"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-03090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-020-03090-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-03090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T23:16:23Z","timestamp":1626563783000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-020-03090-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,18]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3090"],"URL":"https:\/\/doi.org\/10.1186\/s12884-020-03090-9","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,18]]},"assertion":[{"value":"10 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval has been obtained from the Galway Clinical Research Ethics Committee. This study is conducted in accordance with the guidelines of the Declaration of Helsinki and Good Clinical Practice. Written consent has been obtained from all study participants to be part of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}